Ultromics

❤️ Spotlight on EchoGo® Heart Failure for HFpEF detection EchoGo® Heart Failure leverages advanced AI and cardiac imaging to identify patients with Heart Failure with Preserved Ejection Fraction (HFpEF). It provides diagnostic outputs that assist healthcare professionals in diagnosing, managing, and optimizing treatment responses for patients. The technology has been scientifically validated in peer-reviewed journals, demonstrating its efficacy in improving the detection and supporting diagnosis of this challenging subtype of heart failure. Discover the latest research and use cases: ❤️ Clinical Deployment of Ultromics EchoGo® HFpEF Algorithm at Northwestern https://hubs.la/Q02H5rzh0 ❤️Comparison of an Artificial Intelligence Heart Failure Detection Model and Clinical Prediction Models in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) at Beth Israel Deaconess Medical Center and Harvard Medical School https://hubs.la/Q02H5xF_0 ❤️ Unmasking HFpEF with Artificial Intelligence: A Disruptive Opportunity for Disease Detection. https://hubs.la/Q02H5V0_0 ❤️ Automated Echocardiographic Detection of Heart Failure With Preserved Ejection Fraction Using Artificial Intelligence. https://hubs.la/Q02H5FbY0 ❤️Artificial Intelligence to Aid Early Detection of Heart Failure With Preserved Ejection Fraction https://hubs.la/Q02H5GWt0 ❤️ Association of a Novel, Non-invasive AI Model to Automate Echocardiographic Detection of Heart Failure with Preserved Ejection Fraction (HFpEF) with Invasive Hemodynamics. https://hubs.la/Q02H5KRX0 #EchoGo #Ultromics #HFpEF #HeartFailure #Cardiology #AIinHealthcare #Innovation

It’s been another great year for team Ultromics 💙

As we near the end of 2024, we’re reflecting on an amazing year for Ultromics. Thanks to the dedication of our team and the unwavering support of our partners, customers and community, we’ve reached incredible milestones that have brought us closer to redefining the heart failure care pathway, and contributing to the goal of improving patient outcomes. 🌟 Highlights of 2024: 1️⃣ FDA Device Breakthrough Clearance: EchoGo® Amyloidosis became the first — and remains the only — AI echo-based screening tool cleared by the FDA to support Cardiac Amyloidosis detection. 2️⃣ New Partnerships: Ultromics signed partnerships with Pfizer and JNJ Innovative Medicine; A key milestone in advancing their mission to improve early detection and care of Amyloidosis patients. 3️⃣CPT Code Recognition: EchoGo® Heart Failure received a Category III CPT code, a crucial advancement in enhancing the accessibility of Ultromics' technology in hospital outpatient settings. 4️⃣ Research Excellence: Ultromics contributed to more then 15 research publications and abstracts, including 2 late breakers at ESC Congress. 5️⃣ Quality and Security Milestones: Ultromics passed both ISO 13485 and ISO 27001 certifications with zero non-conformities—demonstrating our commitment to the highest standards in quality and data security. 6️⃣ Real World Validation: Ultromics showcased breakthrough research with Mayo Clinic, Northwestern, and Harvard University, highlighting our role in supporting clinical workflows and enhancing heart failure detection. Stay tuned in the new year as we continue to work on new research, partnerships, and innovations to revolutionize heart failure care. Here’s to a an exciting 2025 ahead! 🌍✨ #2024Recap #InnovationInCardiology #FDAApproval #AIInHealthcare #QualityExcellence #Ultromis #EchoGo #Amyloidosis #HFpEF #HeartFailure #Cardiology #EchoFirst #Echocardiography

AI is proving to be a game-changer in the early detection of complex diseases like Cardiac Amyloidosis, which often goes undiagnosed until later stages. Ultromics' EchoGo® Amyloidosis, powered by AI, represents a breakthrough in echocardiography, making it easier for clinicians to flag potential cases.

"This recognition by CMS underscores the significant impact our technology is having in the field of heart failure care,” Ultromics’ CEO and Founder Ross Upton, PhD said.   Ultromics’ EchoGo® Heart Failure now has a new reimbursement code in the Federal Register, enhancing access to life-saving diagnostics. ❤️ The assignment to a clinical APC highlights Medicare’s confidence in the robust clinical validation of Ultromics’ technology. Learn more in their recent article. ⤵️

Dr Faizi A. Jamal reflects on EchoGo® Amyloidosis, the first FDA cleared AI screening tool to help detect Cardiac Amyloidosis from a routine echocardiogram. The technology is helping clinicians with detection and expediting treatment that could impact patient survival. Learn more: https://hubs.la/Q02_X2j20 #EchoGo #Amyloidosis #Ultromics #HeartFailure #AIinHealthCare #Cardiology #PatientCare #HealthTech

Underdiagnosed and difficult to detect, Cardiac Amyloidosis poses significant challenges in healthcare. With advanced AI technologies, cardiac amyloidosis can be identified with precision, aiding timely interventions that could significantly impact survival. Learn how AI is supporting clinicians with detection in our blog: https://hubs.la/Q02_zSdp0 #AIinHealthCare #Innovation #PatientFirst #Cardiology #Ultromics #HeartFailure #Amyloidosis #EchoGo #EuroEcho2024

The Centers for Medicare and Medicaid Services (CMS) has assigned EchoGo® Heart Failure's Category III CPT® billing code to clinical APC 5743, effective January 1, 2025. The assignment to a clinical APC highlights Medicare’s confidence in the robust clinical validation of Ultromics’ technology, underscoring the value of the data and its impact on heart failure care. EchoGo® Heart Failure uses AI to detect Heart Failure with Preserved Ejection Fraction (HFpEF) from a routine echocardiogram, supporting clinicians in detection of people suffering from this disease. The technology sits under the EchoGo® platform, which also includes detection of Cardiac Amyloidosis. The tools are helping clinicians identify complex and underdiagnosed causes of Heart Failure, enabling earlier intervention and accelerating access to life-saving treatments. Discover more about the new billing code assignment: https://lnkd.in/dgs2sYng #HFpEF #Cardiology #Reimbursement #Ultromics #EchoGo #AIinHealthCare #HeartFailure #HeartHealth #PatientFirst

EchoGo® is the only AI powered diagnostic support that detects HFpEF and Amyloidosis using routine echocardiography. EchoGo® is proven to accurately detect patients suffering from these diseases. Seamlessly integrating into existing clinical workflows, EchoGo® delivers diagnostic reports straight to your system, supporting detection and patient management. To find out more about our research and clinical data here: https://hubs.la/Q02_dYwm0 #Cardiology #HFpEF #Amyloidosis #HeartFailure #AIinHealthCare #HeartHealth #Ultromics #EchoGo #EuroEcho2024

We’ll be at EuroEcho to discuss how EchoGo®, our AI-powered platform, is improving Heart Failure detection. With advanced modules for HFpEF and Cardiac Amyloidosis, it detects disease from a single 4-chamber view. Request an appointment: https://hubs.la/Q02_503f0 #Cardiology #HFpEF #HeartFailure #Ultromics #EchoGo #EuroEcho2024 #Amyloidosis #HeartHealth